Related Experiment Video
Updated: Sep 14, 2025

In Utero Intra-cardiac Tomato-lectin Injections on Mouse Embryos to Gauge Renal Blood Flow
Published on: February 4, 2015
Serial Amnioinfusion Therapy for Treatment of Congenital Bilateral Renal Agenesis-A Systematic Review
Adriana Baez1, Gabriele Tonni2, Chryso P Katsoufis3
1Miller School of Medicine, University of Miami, Miami, Florida, USA.
Insights
Serial amnioinfusion therapy (SAT) for congenital bilateral renal agenesis (BRA) shows limited long-term survival benefits. While SAT may improve initial survival, advanced neonatal care is crucial for peripartum survivors.
Area of Science:
- Perinatal Medicine
- Neonatology
- Medical Genetics
Background:
- Congenital bilateral renal agenesis (BRA) is a severe condition with high perinatal mortality.
- Serial amnioinfusion therapy (SAT) has been explored as a potential intervention for BRA.
- The efficacy, safety, and ethical considerations of SAT for BRA require comprehensive evaluation.
Purpose of the Study:
- To systematically review and analyze the outcomes of serial amnioinfusion therapy in cases of congenital bilateral renal agenesis.
- To evaluate the maternal and fetal outcomes associated with SAT for BRA.
- To explore the implications of SAT for BRA management and long-term neonatal survival.
Main Methods:
- A systematic review adhering to PRISMA guidelines was conducted.
- Inclusion criteria involved BRA diagnosis, therapeutic amnioinfusion, and reported maternal/fetal outcomes.
- Data from 11 full-text studies (N=40) focusing on live births with outcome reports were analyzed.
Main Results:
- The average number of SAT sessions was 9 per mother.
- Median gestational age at delivery was 33.4 weeks.
- Neonatal mortality was high at 82.5% (33/40), with 17.5% surviving at publication; nearly half died within 33 days.
Conclusions:
- Serial amnioinfusion therapy for congenital bilateral renal agenesis offers short-term survival benefits but does not consistently improve long-term outcomes.
- Significant advances in neonatal intensive care are necessary to enhance the long-term survival and well-being of peripartum survivors.
- Further research is needed to optimize interventions and improve the prognosis for infants diagnosed with BRA.
Abstract:
Serial amnioinfusion therapy (SAT) has emerged as a potential mitigatory intervention to adverse perinatal outcomes associated with congenital bilateral renal agenesis (BRA). However, its efficacy, safety, and ethical implications warrant thorough evaluation. This systematic review, developed according to PRISMA guidelines, analyzes the published data on outcomes of SAT for BRA and explores its implications. Inclusion criteria were a diagnosis of bilateral renal agenesis, therapeutic use of amnioinfusion, amnioinfusion procedure, and individual maternal and fetal outcome reports. A total of 192 published studies were identified. Among these, 11 full texts were included (N = 40). Only cases resulting in live birth and with reported maternal and neonatal outcomes were analyzed. The average number of amnioinfusions per mother was 9 (n = 23; range 1-26 infusions). Median gestational age at delivery was 33.4 weeks (n = 40; range 23.7-36.8 weeks). APGAR scores (n = 14) at 1 and 5 min were 4 and 6, respectively. Almost half of newborns died within 33 days of life (n = 19) and 7 (17.5%) survived at the time of original publication. Overall neonatal mortality was 82.5% (33 of 40). These findings suggest that SAT for BRA improves the chances of neonatal survival in the first few days to weeks of life but not consistently beyond that time. Additional advances in neonatal care are needed to improve long-term outcomes in peripartum survivors.
Related Concept Videos
Continuous Renal Replacement Therapy
Kidney Transplant II: Surgical Procedure
Acute Kidney Injury V: Interprofessional Care
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Kidney Transplant I: Introduction

